| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |